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CRP has long been used as a non-specific marker of inflammation, and an important biomarker of disease activity in Crohn’s Disease (CD) (J Biol Chem 2004;279:48487-90).  The liver was originally thought to be the only source of CRP synthesis, however recent evidence has suggested human adipocytes as an extrahepatic source of CRP (Annu Rev Immunol 2010;28:157-83).  IL-6 (a potent inducer of hepatic CRP expression) and TNF-α are the main pro-inflammatory cytokines secreted by adipose tissue, suggesting inflammation in mesenteric fat may contribute to increased levels of CRP in CD (Gastroenterology 1999;117:73-81). 

In this study the authors investigated mesenteric adipocytes as a source of CRP expression in patients with CD, and correlation with serum CRP concentrations.  The impact of inflammatory and bacterial challenges on CRP expression by mesenteric adipocytes using an adipocyte cell line (3T3-L1 cells) was examined. Furthermore bacterial translocation to mesenteric fat was studied in experimental models of colitis and ileitis and in patients with CD.  The authors prospectively recruited a cohort 22 patients with CD, 17 with Ulcerative Colitis (UC) and 21 controls (with colorectal malignancy (n=19) or diverticulitis (n=2)).  Biopsies of mesenteric and subcutaneous adipose tissues, and healthy and inflamed colonic tissue were taken during surgery, with histological examination to confirm the absence of inflammation on intestinal on intestinal biopsies and to select fat specimens at a distance from mesenteric lymph nodes. 

Using real-time PCR, levels of CRP mRNA expression were 105-fold higher in mesenteric adipose tissue of patients with CD was observed compared to the UC and control groups. There was no observed difference between mesenteric CRP mRNA expression in the UC and control groups, or in CRP mRNA expression in subcutaneous adipose tissue of all groups. To further investigate over-expression of CRP in mesenteric adipose tissue in CD, paired mesenteric and adipose tissue samples in the same patient were compared (n=6).  Unlike in UC and control groups subjects (where observed CRP mRNA levels were similar in mesenteric and subcutaneous adipose tissues), CRP mRNA was over-expressed 140-fold in mesenteric fat compared to subcutaneous fat in patients with CD.

To investigate whether the adjacent intestine was a source of local CRP, they compared intestinal and mesenteric adipose tissue CRP mRNA levels in patients with and without CD. Observed CRP mRNA levels were significantly higher in mesenteric adipose tissue than in the intestinal tissue of the same patients, and were 217500±67500 times higher in the CD patients, due to mesenteric adipose tissue hyperplasia in this group.  They confirmed mesenteric adipocytes as a source of CRP at the protein level using western blot analysis, thus suggesting intestinal tissue is not a local source of CRP.  

To confirm whether mesenteric adipose tissue CRP overexpression is a potential source of CRP in the serum of CD, the authors examined the ability of mesenteric adipose tissue to release CRP by comparing mesenteric CRP levels with paired serum CRP levels in patients with CD.  They observed a strong positive correlation between mesenteric CRP transcript levels and plasma CRP levels, whereas no correlation was observed in UC and control subjects, therefore suggesting CRP released by mesenteric fat may be in part responsible for elevated plasma CRP levels in patients with CD. 

To examine the mechanisms by which mesenteric adipocyte CRP expression is triggered, the authors measured CRP mRNA levels according to differentiation and activation states of adipocytes.  A 21±2.5 fold induction of CRP mRNA expression was observed during differentiation of 3T3-L1 pre-adipocytes, paralleled by an increase in aP2 mRNA levels (a well-established marker of terminal adipocyte differentiation), indicating CRP expression is dependent upon adipocyte differentiation. Furthermore independent treatment of mature adipocytes with TNFα, IL-6, E coli infection and LPS (a structural component of the outer wall of gram negative bacteria) resulted in a significant increase in CRP mRNA levels. In comparison, stimulation with a control gram positive-lactobacillus strain lead to no observed significant increase in CRP synthesis by adipocytes. 

Finally, the authors used a mouse model of dextran sulphate sodium (DSS)-induced colitis to investigate bacterial translocation from the gastrointestinal tract to mesenteric lymph nodes.  Bacterial translocation to mesenteric adipocytes occurred spontaneously in 15% of control mice but was enhanced in all mice with DSS-induced colitis. Furthermore, significantly higher rates of bacterial translocation to mesenteric lymph nodes were observed in mice receiving DSS compared to control mice, however rates of bacterial translocation to mesenteric adipose tissue and mesenteric lymph nodes in DSS-treated mice were broadly similar.  Experimentation using indomethacin-induced ileitis in rats, yielded similar observations with significantly increased rates of bacterial translocation to mesenteric adipose tissues in indomethacin-treated rats compared to control rats. Consistent with animal studies, the observed rate of bacterial translocation to mesenteric adipose tissue in patients with CD (n=22) was similar to that observed in mesenteric lymph nodes.  However when compared to control and UC subjects the rate of bacterial translocation to mesenteric adipose tissue was not significantly higher in patients with CD, perhaps an effect of small sample size. Furthermore the rates of bacterial translocation to mesenteric lymph nodes in patients with CD did not reach statistical significance in comparison with UC and control groups. 

In summary, this study demonstrates mesenteric adipose tissue is an important source of CRP in CD.  CRP production by mesenteric adipocytes may be triggered by local inflammation and bacterial translocation to mesenteric fat, providing a mechanism whereby mesenteric fat hyperplasia may contribute to inflammatory response in CD. 

Comment
Fat-streaking identified on CT imaging and during colonic surgery has long since been used as a marker to locate areas of inflamed colonic tissue.  Such practices were evident long before studies demonstrated mesenteric fat hyperplasia to be a characteristic feature of CD (Gut 2007;56:577-83).  Mesenteric fat hyperplasia is not a characteristic feature of UC and CRP levels in CD are higher for all levels of disease activity compared to UC, providing further evidence for mesenteric adipose tissue as a source for CRP in CD (Eur J Clin Invest 2008;12:351-359).

High serum concentrations of CRP are of clinical significance in CD as they correlate with poor prognosis, increased relapse rate following withdrawal of medical therapies, and greater response rate to anti-TNFα therapies (Gut 2008;57:1518-23, Gastroenterol Hepatol 2009;7:80-5).  Some studies have suggested plasma CRP levels are not well correlated with mucosal lesions observed on endoscopy (Gut 1994;35:231-235).  In support of this, Peyrin-Biroulet and colleagues’ study observed that CRP mRNA expression was similar in the intestinal tissue of those patients with and without active CD, confirming intestinal tissue is not a significant source of CRP.  However in contrast, mesenteric adipose tissue (fat-wrapping) has been correlated with transmural inflammation and stricture formation (Br J Surg 1992; 79955–958.958). The authors comment that they have not excluded the liver as a significant source of CRP in CD as they were able to undertake portal vein sampling. This is particularly relevant as the authors demonstrated that IL-6 could stimulate CRP production in their in vitro studies with pre-adipocytes and the liver is a significant source of CRP.

A number of factors determine CRP response in CD patients. A proportion of patients with CD do not mount a CRP response despite clinically obvious inflammatory activity. Polymorphisms of the CRP gene have a significant effect on serum levels. Patients with the C allele of the CRP +1059G/C polymorphism have low levels of serum CRP. This polymorphism is particularly prevalent in CD patients with ileal involvement (Alimentary Pharmacology and Therapeutics 2006;24:1105-15). Low serum CRP levels correlate with poor response to anti-TNF therapy. Further investigation is required between CRP polymorphisms and anti-TNF therapy. Whilst CRP levels are positively correlated with body mass index in obese individuals, derived from both liver and adipose tissue, the CD patient population are not typically obese (Am J Gastroenterol 2006;101:1824-33).  Despite this, there has been consistent reporting of reduced growth hormone levels in patients with CD (J Clin Endocrinol Metab. (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed​/​15572428" \o "The Journal of clinical endocrinology and metabolism.​) 2005;90:768-74). Growth hormone modulates adipose tissue and deficiency commonly leads to increased centripetal adiposity, which may contribute to mesenteric adipose tissue production in CD.  Notably, patients with CD and a persistently low CRP in the face of active disease are characterized by a low BMI and almost exclusive ileal disease (Scand J Gastroenterol 2006;41:306-11).  However in this low-CRP group, mesenteric fat wrapping (defined as mesenteric adipose tissue extension from the mesenteric attachment and partially covering the small or large intestinal circumference in association with loss of the bowel‐mesentery angle) was still noted in the majority of patients undergoing ileal resection (Gut.2007;56:577-83).  Whilst Peyrin-Biroulet and colleagues observe CRP mRNA levels to be significantly higher in mesenteric adipose tissue of CD patients, compared to subcutaneous adipose tissue, further investigation into whether BMI or disease activity correlates with degree of mesenteric adiposity in CD patients may be justified. 

Anti-TNFα agents are now commonly used in the treatment of severe or refractory CD.  TNFα is the main pro-inflammatory cytokine expressed by mesenteric adipose tissue of CD patients, which is not found in the mesenteric tissue of control patients (Gastroenterology 1999;81:11773-81). Increased release of leptin (a satiety hormone that reflects adipose tissue mass and signals energy sufficiency to the hypothalamus resulting in increased energy expenditure and anorexia) has been observed during (in vivo) injection of TNFα in mice (J Clin Invest 100:2777–2782). During an acute inflammatory process, leptin production can induce anorexia and weight loss, but during chronic inflammation (such as in CD) leptin levels diminish (J Clin Endocrinol Metab 85:530–535). Such suppression may explain the mesenteric adipose tissue expansion observed in patient with CD.  Infliximab treatment that induces a clinical and biological response (including reduction in CRP) also results in increased serum leptin levels, through alleviating the negative inhibitory effect of TNFα (J Clin Endocrinol Metab, June 2005, 90(6):3510–3516). The increase in serum leptin levels paradoxically appears to result in increased weight gain in patients with CD, but to be independent of fat-mass.  This may explain the reduction in CRP levels observed post-Infliximab treatment. Further investigation into whether mesenteric adiposity correlates with serum leptin levels in patients with CD may be warranted. 

The authors’ observations that in CD bacteria translocate to the mesenteric adipose tissue in CD is novel and provides further confirmation that gut bacteria play a crucial role in the pathogenesis of CD (Gut 2008 Apr;57(4):429-33). Loss of intestinal barrier function through increased cell shedding has been shown to predict relapse in CD, presumably through increased bacterial translocation and antigen entry (Gut 2012 (In press)). Further studies correlating these parameters are required together with studies on the mechanisms of bacterial recognition in mesenteric adipocytes, for example by Toll-like receptors and NOD2.

This study by Peyrin-Biroulet and colleagues emphasises the importance of mesenteric adipose tissue in the disease process of CD.  Notably this study shows that mesenteric adipose tissue is an important regional source of CRP in CD.  Whilst CRP levels have been correlated with poor prognosis and increased response to biological therapies, further work to assess whether mesenteric fat hypertrophy is associated with a more aggressive subtype of CD is needed. 





PAGE  



7



